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In their recent paper, Tafuri et al. [1] argue that although a
drug is used in an off-label manner in children, enough
evidence may be available from existing studies to not
warrant further studies. As researchers in pediatric clinical
pharmacology and practicing clinicians, we strongly sup-
port this approach. The use of data from existing, often
investigator-initiated, studies to determine the appropriate-
ness of off-label use of drugs may greatly reduce the burden
on children to participate in possibly unnecessary studies.
In their paper, these authors propose that the availability
of empirical data from two pharmacokinetic (PK) and two
efficacy studies in children is enough to waive additional
studies. In this respect, we would like to emphasize the
impressive physiological changes and, consequently, PK
and pharmacodynamic (PD) changes that occur in children
over the whole age continuum [2]. In order to account for
these developmental changes, three aspects of drug trials in
children should be taken into account when available
studies are being assessed: the choice of the dose, the
choice of the group (age and disease) and the choice of the
endpoints to measure the effect of the drug. If these aspects
are not adequately addressed in the trial (design), the
researcher(s) may arrive at the wrong conclusion(s) and
subsequently impose on children a treatment that lacks
efficacy or, even worse, expose them to the risk of drug
toxicity.
An example of how the choice of the dose may lead to
incorrect study conclusions is a randomized clinical trial of
diphenhydramine in children reported in 2006 [3]. In this
trial, where bodyweight-corrected adult doses of diphenhy-
dramine were used in infants, no effect of the drug on sleep
was observed in this population [3]. However, the size-
corrected clearance of the drug was found to be much
higher in infants than in adults [4]. It may therefore be
concluded that the doses used in the efficacy study were
probably too low to reach drug concentrations associated
with sleep in adults.
This example stresses the need to take into account age-
related differences in the dose-concentration relationship
between children of different ages and adults when
interpreting efficacy studies. In addition, treatment indica-
tions, disease processes, outcome of therapy and the
concentration–effect relationship may also differ for chil-
dren of different ages. Hence, the effect of age on all of
these determinants of drug therapy outcome should be
considered before data from children of one age group are
used to waive the need for studies in another age group. As
such, in this context, it is evident that the availability of
data from two PK and two efficacy studies of a protein
pump inhibitor (PPI) for the treatment of heartburn
complaints in adolescents should not be used to waive
studies on the efficacy of a PPI for respiratory symptoms
related to gastroesophageal reflux disease in preterm
infants. More specifically, most of the studies reported in
the article of Tafuri et al. [1] were performed in children
older than 1 or 2 years. However, it is known that the
largest developmental changes in PK and PD are likely to
occur in the age range younger than 1 year and that these
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Leiden, The Netherlandsare the most striking during the first weeks of life. These
developmental changes necessitate that studies be per-
formed in the youngest age groups as well before
conclusions on the use in the entire group of children can
be drawn. Additionally, the effect of the drug in children
should be measured using validated age-appropriate end-
points, which may vary between the youngest children
versus older children and adults.
We agree with Tafuri et al. [1] on the need to incorporate
existing knowledge and would like to specify the potential
role of population PK–PD modeling. This tool allows for
the analysis of existing in vitro and in vivo data from
children, which results in the design of dosing guidelines
for children of different ages without the need for extensive
clinical trials [5]. Additionally, this approach also allows for
minimization of the need for additional studies in children
because developmental changes in PK and PD can be
characterized even when only sparse sampling is applied. In
case data are lacking in specific age groups of for specific
indications and additional studies are thus needed, the use
of limited sampling strategies based on simulations using
population PK-PD modeling will reduce the burden for
individual patients [5].
Finally, it is important to address the question of whom
should be responsible for assessing the appropriateness of
the use of an off-label drug in children. Currently, this
responsibility has been left with the treating physician,
guided by clinical guidelines or information from drug
formularies—if these are available at all. We believe that
this responsibility should reside with the regulator(s). The
regulator has not only access to published study data but
also to unpublished data from the manufacturer. These
existing data should be carefully evaluated by regulators
with expertise in developmental pharmacology and appro-
priate modeling techniques. The regulator can then decide,
based on this evaluation, whether to waive or reduce the
need for additional studies and grant a license for the
appropriate age range and treatment indication—or not.
While this would mean a substantial effort by the regulatory
authorities, such a procedure would lead to major improve-
ment in pharmacotherapy in children, from both an ethical
and medical point of view.
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